Literature DB >> 19568929

Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer.

Einar Gudlaugsson1, Ivar Skaland, Emiel A M Janssen, Paul J van Diest, Feja J Voorhorst, Kjell Kjellevold, Axel zur Hausen, Jan P A Baak.   

Abstract

Evaluation of prognostic factors in lymph node negative (LNneg) invasive lobular cancers (ILCs). Prospective analysis of proliferation and other prognosticators in 121 LNneg ILCs (119 months median follow-up, range 19-181), without adjuvant chemotherapy. ILC subtype was assessed in accordance with WHO-2003 criteria. Immunohistochemical E-cadherin and estrogen receptor were used. With a median follow up time of 83 months (range 19-181), 30 of the 121 (25%) ILC patients developed distant metastases and 27 (22%) died. None of the cases classified as solid/pleomorphic lobular were E-cadherin or estrogen receptor positive, contrasting the other ILCs. The solid/alveolar ILCs (n = 17) had a worse survival (50%) than the other ILCs (n = 104; 83%, P < 0.0001). Mitotic activity index (MAI) (but not nuclear grade or tubule formation) was prognostic with a threshold 0-5 versus >5 (=MAI-5) (contrasting MAI < 10 vs. > or = 10 in breast cancers in general; 85 and 54% survival, P < 0.0001). In multivariate analysis only subtype and MAI but none of the other characteristics had independent prognostic value. Histologic subtype and MAI have independent prognostic value in node negative invasive lobular cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19568929     DOI: 10.1007/s10549-009-0442-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.

Authors:  Patrick W B Derksen; Tanya M Braumuller; Eline van der Burg; Marten Hornsveld; Elly Mesman; Jelle Wesseling; Paul Krimpenfort; Jos Jonkers
Journal:  Dis Model Mech       Date:  2011-01-31       Impact factor: 5.758

2.  p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast.

Authors:  Cigdem Ercan; Paul J van Diest; Bram van der Ende; John Hinrichs; Peter Bult; Horst Buerger; Elsken van der Wall; Patrick W B Derksen
Journal:  Cell Oncol (Dordr)       Date:  2012-02-22       Impact factor: 6.730

3.  Methylation biomarkers for pleomorphic lobular breast cancer - a short report.

Authors:  Cathy B Moelans; Eva J Vlug; Cigdem Ercan; Peter Bult; Horst Buerger; Gabor Cserni; Paul J van Diest; Patrick W B Derksen
Journal:  Cell Oncol (Dordr)       Date:  2015-09-21       Impact factor: 6.730

4.  Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.

Authors:  Julia E C van Steenhoven; Anne Kuijer; Robert Kornegoor; Gijs van Leeuwen; Joost van Gorp; Thijs van Dalen; Paul J van Diest
Journal:  Histopathology       Date:  2020-08-30       Impact factor: 5.087

5.  The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.

Authors:  Marie Klintman; Carina Strand; Cecilia Ahlin; Sanda Beglerbegovic; Marie-Louise Fjällskog; Dorthe Grabau; Einar Gudlaugsson; Emiel A M Janssen; Kristina Lövgren; Ivar Skaland; Pär-Ola Bendahl; Per Malmström; Jan P A Baak; Mårten Fernö
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

6.  Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients.

Authors:  Kjersti Tjensvoll; Oddmund Nordgård; Maren Skjæveland; Satu Oltedal; Emiel A M Janssen; Bjørnar Gilje
Journal:  BMC Cancer       Date:  2019-11-21       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.